Talvey (Talquetamab)

Talvey (talquetamab-tgvs) is a bispecific GPRC5D-directed CD3 T-cell engager used for the treatment of adult patients with relapsed or refractory multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent and an anti-CD38 monoclonal antibody. 

Recommended Dosage: The recommended dosages of Talvey subcutaneous (SC) injection are: step-up dose 1 of 0.01 mg/kg on Day 1, step-up dose 2 of 0.06 mg/kg on Day 4, followed by the first treatment dose of 0.4 mg/kg on Day 7, and then 0.4 mg/kg once weekly thereafter.

• Treatment with Talvey can cause cytokine release syndrome, including life-threatening or fatal reactions. Start therapy with step-up dosing and administer pre-treatment medicines (such as corticosteroids, antihistamine, and antipyretics) before each dose in the step-up dosing schedule to reduce the potential of CRS. Monitor patients after administration accordingly.
• Talvey 3 mg/1.5 mL injection can cause life-threatening, or fatal neurologic toxicity, including ICANS. Assess patients for symptoms of neurologic toxicity during therapy. At the initial sign of neurologic toxicity, including ICANS, promptly evaluate the patient and provide supportive care on behalf of severity; withhold or permanently stop treatment on behalf of severity.
• Talquetamab-tgvs can cause weight loss, and oral toxicities, including dry mouth, dysgeusia, dysphagia, and stomatitis. Monitor patients for the symptoms of oral toxicity. Monitor weight regularly throughout therapy. Evaluate clinically significant weight loss further. Withhold therapy or permanently stop on behalf of severity.
• This medicine can cause critical infections, including life-threatening or fatal infections. Monitor patients for symptoms of infection before and throughout treatment and treat appropriately. Administer prophylactic antimicrobials as per local guidelines. Withhold or consider permanent discontinuation of treatment as recommended on behalf of severity.
• Talvey injection can cause serious skin reactions, including erythema, rash, maculo-papular rash, and erythematous rash. Monitor for skin toxicity, including rash progression. Consider early intervention and treatment to manage skin toxicity. Withhold therapy is recommended based on severity.

What documents are required to import TALVEY to India?

TALVEY (talquetamab-tgvs) injections can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patients ID proof (issued by the government of India)

The order will be confirmed only after the receipt of:

• A valid prescription from Doctor
  
• Import permit if applicable

TALVEY (talquetamab-tgvs injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Talvey in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

IPN (Indian Pharma Network) can facilitate the supply of TALVEY (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Talvey 3 mg/1.5 mL price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network is able to source the TALVEY (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Talvey®?

Talquetamab-tgvs is a Generic Name for the trade name drug Talvey®.

What is the Manufacturer’s Name of Talvey®?

Talvey® is manufactured by Janssen Biotech, Inc.

Is Talvey® approved by the FDA?

Yes, Talvey® is approved by the FDA. Date of first approval: August 9, 2023.

Where can I get Talvey® at the best price in India?

To get the best Talvey 40 mg/mL price in India, kindly contact the Indian Pharma Network (a WHO GDP and ISO 9001:2008 certified company). For Talvey®, a medical prescription is needed from a treating physician.

What is the dosage and form of Talvey® supplied?

Talvey® is supplied as Injections: 3 mg/1.5 mL (2 mg/mL) and 40 mg/mL in a single-dose vial for subcutaneous use. 

What are the most common side effects of Talvey®? 

The most common side effects of Talvey® are nail disorder, pyrexia, CRS, dysgeusia, musculoskeletal pain, dry mouth, skin disorder, rash, fatigue, weight decreased, xerosis, dysphagia, upper respiratory tract infection, hypotension, diarrhea, and headache.

How much does Talvey® cost in India?

The cost of Talvey in India can vary. To procure this therapeutic drug legally, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Talvey®?

Store refrigerated at 2 to 8°C (36 to 46°F) in the original carton to protect from light. Do not freeze the product.  

Is it safe to buy Talvey® online in India?

Yes, one can buy Talvey online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Talvey® through legal channels.